Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be led by CEO Vipin Garg and CMO Scott Harris, with a pre-recorded session available on September 13 at 7 a.m. EST. Altimmune focuses on developing treatments for obesity and liver diseases, including therapies like ALT-801 for NASH and HepTcell™ for chronic hepatitis B. For further details, visit Altimmune's website.

GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23^rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.

Details on the H.C. Wainwright fireside chat presentation are as follows:

	Title:		H.C. Wainwright 23rd Annual Global Investment Conference
	Presenters:		Vipin Garg, Ph.D., Chief Executive Officer
			Scott Harris, M.D., Chief Medical Officer
	Date/Time:		Monday, September 13, 2021 (virtual pre-record available at 7 a.m. EST)

A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Will Brown                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
wbrown@altimmune.com

FAQ

What is the date and time of Altimmune's presentation at the conference?

Altimmune's presentation at the H.C. Wainwright conference is scheduled for September 13, 2021, with a virtual pre-record available at 7 a.m. EST.

Who will present on behalf of Altimmune at the H.C. Wainwright conference?

Vipin Garg, CEO, and Scott Harris, CMO, will represent Altimmune during the presentation.

Where can I watch Altimmune's presentation?

Altimmune's presentation can be accessed via a webcast link available on their website in the Events section.

What is Altimmune's focus in biopharmaceuticals?

Altimmune focuses on developing treatments for obesity and liver diseases, including next-generation peptide therapeutics.

What are the key products in Altimmune's pipeline?

Altimmune's pipeline includes ALT-801 for NASH and HepTcell™ for chronic hepatitis B.